Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.52 |
| ▸ | CDC25A | P30304 | 3/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22872157 | 1.00 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL24632922 | 1.00 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL30088637 | 1.00 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9829516 | 0.91 | NPC1L1 (0.49) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL11778820 | 0.90 | NPC1L1 (0.48) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9827579 | 0.90 | NPC1L1 (0.45) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL11413520 | 0.89 | NPC1L1 (0.52) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL26669399 | 0.89 | GPBAR1 (0.47) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9829186 | 0.89 | GPBAR1 (0.47) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL3137808 | 0.89 | NPC1L1 (0.54) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010071772-A2 | SYNTHESIS OF 3B-AMINO-5-CHOLESTENE AND RELATED 3B-HALIDES INVOLVING I-STEROID AND RETRO-I-STEROID REARRANGEMENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160657-A1 | SYNTHETIC MIMICS OF MAMMALIAN CELL SURFACE RECEPTORS: METHOD AND COMPOSITIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160657-A1 | SYNTHETIC MIMICS OF MAMMALIAN CELL SURFACE RECEPTORS: METHOD AND COMPOSITIONS | NR1H4, LDLR, NR1H3 | NPC1L1 11/4885USP2 3383/4885LMNA 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.